BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Ajanta Pharma Ltd. posted in-line Q4 FY22. Superior show in Asia/domestic formulation/Africa (branded generics) was offset by increased competition in the U.S. generics market and incremental cost pressures.
We have cut our FY23E/FY24E earnings per share by 6%/7%, respectively, to factor in increased raw material/supply chain costs, higher price erosion in the U.S. generics and muted institutional anti-malaria sales.
We believe Ajanta Pharma will sustain outperformance in the branded generics segment aided by new launches, market share gains in existing products and price hikes to some extent.
While the near-term outlook would be subdued, the higher pace of filings/approvals would improve the growth prospects in the U.S. generics segment.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR